The Globe and Mail reports in its Friday, July 4, edition that Haywood Securities analyst Gianluca Tucci has reaffirmed his "buy" recommendation for Kits Eyecare. The Globe's David Leeder writes in the Eye On Equities column that Mr. Tucci gave his share target a $3 boost to $21. Analysts on average target the shares at $17.93. Mr. Tucci says in a note: "Kits Eyecare is well-positioned to continue delivering outsized growth and leading the industry's charge from bricks-to-clicks. Our DCF-based target price moves higher on refreshed forward estimates and a lowered discount rate to 14 per cent from 15 per cent, reflecting the company's robust financial standing." The Globe reported on April 12, 2024, and Nov. 8, 2024, that Stifel analyst Martin Landry continued to rate Kits Eyeware "buy." It was then worth $6.41 and $9.03. The Globe reported on March 7, 2025, that Ventum Capital Markets analyst Devin Schilling had reaffirmed his "buy" recommendation for Kits Eyecare. The shares could then be had for $9.30.